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Summary 5,160 non-hysterectomised women aged 44-100 years completed a health survey questionnaire as
part of a longitudinal study of a southern California retirement community begun in June 1981. As of 1
January 1987, 50 incident cancers of the endometrium had occurred among these women, who had
contributed 23,786 years of follow-up. Women who had used oestrogen replacement therapy had a relative
risk of endometrial cancer of 10 compared to women who had never used oestrogens (P<0.0001). Risk
increased with increasing duration of use (X2 test for trend=50.60, P<0.0001); women who had used
oestrogens for 15 or more years had a relative risk of 20 (95%C.I.=7.2, 54) compared to non-users. While
current and recent users (i.e. those who had used oestrogen within one year of the initial survey) had the
greatest risk (RR=25, 95%C.I.=9.2, 69), women who had last used oestrogens 15 or more years ago still
had a significantly increased risk (RR =5.8, 95% C.I. =2.0, 17). No other variable studied had a major effect
on risk, except smoking. Women who smoked at the time of menopause had a significantly reduced risk of
disease (RR=0.38, P=0.005), which was essentially unchanged after adjustment for oestrogen use.
It is well established that post-menopausal women who use
oestrogen replacement therapy are at increased risk of
endometrial cancer (Smith et al., 1975; Ziel & Finkle, 1975;
Mack et al., 1976; McDonald et al., 1977; Gray et al., 1977;
Autunes et al., 1979; Weiss et al., 1979; Jick et al., 1979;
Jelovesk et al., 1980; Shapiro et al., 1980; Hulka et al.,
1980). Most studies which have explored this association
have been of the case-control design. The appropriate
control series for such studies has been the topic of consider-
able scientific concern (Horwitz & Feinstein, 1978). Few
prospective studies have evaluated the strength of this asso-
ciation (Hoover et al., 1976; Persson et al., 1986) and few of
the case-control studies have contributed information on risk
after lengthy periods off therapy. This paper reports the
results of a large cohort study in which the prevalence of
past oestrogen use was high.
Methods
In June 1981 a health questionnaire was mailed to all
residents of Leisure World, Laguna Hills, a retirement
community near Los Angeles, California. New residents who
moved into the community after this date were mailed the
questionnaire in June 1982, June 1983 and October 1985.
Residents of this community are almost entirely white,
moderately affluent and well educated. The residents' median
age was 73 years at the time of the initial mailing and about
two-thirds were women. After three mailings, 13,986 (61%)
of the 22,781 residents returned questionnaires; 8,882 of
these respondents were women.
The health questionnaire requested information on certain
prior medical diagnoses including cancer; height and weight;
use of cigarettes and alcohol; and for women, menstrual and
reproductive events, including gynaecological surgeries.
Detailed information was collected on use of oestrogens
during menopause including routes of administration (injec-
table, oral, vaginal) and duration of therapy. For the most
commonly used oral oestrogen, Premarin, pill colour was
used to help identify the dosage(s) taken.
Pathological diagnosis of cancer among cohort members
are obtained from five local hospitals. Surveys among
community residents suggest that over 85% of inpatient
hospital care occurs in these hospitals. The cohort is also
followed for deaths using the death certificate records of the
Correspondence: A. Paganini-Hill.
Received 28 June 1988; and in revised form 2 November 1988.
local county health department. Death certificates are
obtained for additional decedents identified by the commun-
ity business office, from the obituary columns of the local
newspaper, and from information provided by relatives and
friends. In addition, we have conducted a biennial remailing
to the cohort. To date only 13 cohort members have been
lost to follow-up; search of the National Death Index did
not reveal that these individuals were deceased.
Age-adjusted mortality rates were computed by direct
standardisation using an internal standard (i.e. the person-
years distribution of the total cohort under study) and four
age groups. Relative risks and P values were obtained using
a regression method that assumed that the occurrence of
death could be regarded as a Poisson process with a constant
hazard rate for a given person (Breslow et al., 1980). The
GLIM statistical software package program (Royal Statisti-
cal Society, 1978) was used to make these calculations. All
reported P values are two-sided.
Results
As of 1 January 1987, 50 women had been diagnosed as
having endometrial cancer among the 5,160 women who
indicated they had not had uterine cancer and/or a hysterec-
tomy on the initial questionnaire. Seven of these 5,160
women provided no information on oestrogen use and were
excluded from further analyses related to this variable. The
age-specific and age-adjusted rates for endometrial cancer by
history of oestrogen use are given in Table I. There were 45
endometrial cancers among the women who had used oestro-
gen replacement therapy and five among those who had
never used oestrogens, yielding an age-adjusted relative risk
(RR) of 10 (P<0.0001).
Duration was evaluated as the total number of years of all
types of oestrogen replacement therapy, regardless of route
of administration. Dose was only available for women taking
oral conjugated oestrogens. The reported dose is that taken
for the longest period of time. Eighty-nine per cent of
oestrogen users had used oral oestrogen for at least part of
the time, and 62% had used only this form of oestrogen
replacement therapy.
Years since last oestrogen use was strongly associated with
risk of endometrial cancer (X2 for trend=51.82, P<0.0001).
The highest risk was found in women who were currently
using oestrogen or who had taken it within one year of
completing the original questionnaire (RR=25 compared to
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Table I Age-adjusted endometrial cancer incidence rates per
1,000 and number of cases by use of oestrogen replacement
therapy
Number Incidence Relative
Woman-years of cases rate risk
Any oestrogen use
Never 12,472 5 0.3 1.0
Ever 11,281 45 2.9 10
Duration of oestrogen use
,<2 3,888 8 2.1 5.2
3-7 2,607 7 3.1 7.0
8-14 2,336 13 4.9 4
15+ 2,134 17 7.6 20
Years since cessation of oestrogen
15+ 4,202 10 2.1 5.8
8-14 2,372 7 2.7 8.1
2-7 2,366 10 3.4 12
0-1 2,076 18 8.4 25
Dose of oestrogen
<0.625 3,423 20 5.3 15
>1.25 2,996 13 4.1 11
Table III Age-adjusted endometrial cancer incidence rates per 1,000
and number of cases by other potential risk factors
Woman- Number Incidence Relative
years of cases rate risk
Weight (lb)
<120
121-138
139+
7,928
7,968
7,834
17
19
14
Weight at last menstrual period (lb)
< 122 7,857 15
123-135 7,842 25
136+ 6,889 9
Years since last PAP test
< 1 14,712 39
2-5 5,422 9
6+ 2,111 1
Smoking at last menstrual period
No 16,218 42
Yes 7,475 8
aTest for trend.
1.00
1.10
0.82
1.00
1.68
0.70
2.1
2.4
1.8
1.9
3.2
1.3
2.6
1.6
0.5
1.00
0.63
0.19
2.7 1.00
0.9 0.38
P =0.02'
P =0.005
never users, 95%C.I.=9.2, 69). However, women who had
stopped taking oestrogens as long ago as 15 years still had a
RR of 5.8 (95%C.I.=2.0, 17) compared to non-users.
Duration of oestrogen replacement therapy was also
strongly related to risk of endometrial cancer. Risk increased
significantly with increasing duration of use (X2 for
trend=50.60, P<0.0001). Women who had taken oestrogen
for 15 or more years had a risk of 20 compared to never
users (95%C.I.=7.2, 54).
Ninety-two per cent of the women who reported having
taken Premarin were able to report the dosage(s) taken (78%
of oral oestrogen users reported they had taken Premarin).
Women who had used primarily a high pill dose (>1.25mg
conjugated equine oestrogen) had a relative risk similar to
that of women who had used a lower dose. However, we had
only 13 endometrial cancer cases among the high dose group
and 20 cases among the lower dose group. In both groups
the highest risk was seen for long-term and recent users of
oestrogen.
Data on intervals after cessation of oestrogen use, strati-
fied according to duration of use, are presented in Table II.
Both duration and time since last use were independently
related to risk of endometrial cancer. The highest risk
(RR =34) was observed for recent long-term users (15 +
years).
No other variable studied (age at menarche, parity,
number of children, age at last menstrual period, weight,
alcohol use) was significantly related to the development of
endometrial cancer except smoking and years since last PAP
test (Table III). Women who were smokers at the time of
their last menstrual period had a RR of 0.38 compared to
non-smokers (P=0.006). After adjusting for oestrogen use,
Table II Age-adjusted endometrial cancer incidence rates per 1,000
and number of cases by duration of and years since cessation of
oestrogen replacement therapy
Years since Woman- Number Incidence Relative
Duration cessation years of cases rate risk
None No use 12,472 5 0.3 1.0
3 0-1 352 0 - -
2-14 1,354 4 3.7 8.8
15+ 2,776 7 2.3 6.2
4-14 0-1 821 7 8.1 27
2-14 2,313 8 2.6 9.8
15+ 1,189 2 1.3 4.0
15+ 0-1 865 11 11.8 34
2-14 1,056 5 4.8 12
15+ 213 1 2.5 7.2
this RR was essentially unchanged (RR=0.36) and statisti-
cally significant (P=0.004). Years since cessation of oestro-
gen use was highly correlated with years since last PAP test.
Some 87% of women who had used oestrogen within the last
year had had a PAP test within the last year versus 81% of
women who had used ERT 2-7 years ago, 66% of women
who had used ERT 8 or more years ago and 59% of women
who had never used ERT.
The five non-oestrogen users who developed endometrial
cancer were all over 80 years of age at the time of diagnosis
and all were non-smokers at the time of menopause (versus
71% of the women without endometrial cancer who had
never used oestrogen). Three cases had never been pregnant
versus 28% of the non-cases. Otherwise there were no
outstanding differences between cases and non-cases among
the non-users of oestrogen.
Ten women diagnosed with endometrial cancer have died
(three non-oestrogen users), six from their endometrial
cancer (two non-oestrogen users), two from ischaemic heart
disease (one non-oestrogen user), one from bronchiectasis
and one from lymphoma. The 3-year survival rate was 85%
and 60% for oestrogen users and non-users, respectively.
Discussion
While our data on both oestrogen use and other variables
are self-reported, we have evidence that these data are both
reliable and valid (Paganini-Hill & Ross, 1982). Previous
studies of oestrogen use in this community have found
extremely good correlation in relative risks for various
chronic diseases when oestrogen use was ascertained by
interviews, medical records or pharmacy records (Mack et
al., 1976; Ross et al., 1980; Paganini-Hill et al., 1981).
This study confirms in a population-based cohort that the
risk of endometrial cancer increases sharply with increasing
duration of usage of oestrogen replacement therapy. We
found no clear effect of pill dose on risk. Although this did
not appear to be due to longer duration of use in women
using the lower pill dose, the number of cases did not permit
a detailed evaluation of this proposition. Twenty-six per cent
of Premarin users in our cohort reported using multiple pill
doses. The risk remains substantially elevated even after 15
years since cessation of use. Other reports have shown that
the elevated risk persists after cessation of oestrogen use
(Mack et al., 1976; Weiss et al., 1979; Shapiro et al., 1985),
but this study extends the risk to longer drug-free intervals.
One previous study suggested that the risk of endometrial
cancer abates rapidly within two years since cessation of use
(Hulka et al., 1980), but most oestrogen use in that study
was of short duration (<3 years). Because of the long-
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lasting effect of oestrogen use on the risk of endometrial
cancer, it is imperative that women who have used oestrogen
replacement therapy, especially for long periods of time, be
continually followed gynaecologically. Our results pertain
almost exclusively to oral oestrogens used as conjugated
equine preparations. Combination hormone replacement
therapy (oestrogen plus progestin) is a relatively recent
alternative therapy in the USA. Only about 1% of women in
our cohort have ever used such treatment.
The observation that cigarette smoking is protective
against the development of endometrial cancer is not surpris-
ing. Several recent case-control studies have reported similar
results (Baron et al., 1986; Lesko et al., 1985). This may be
due to an anti-oestrogenic effect of smoking. Women who
smoke have lower urinary excretion rates of endogenous
oestrogens (MacMahon et al., 1982; Jensen et al., 1984) and
lower serum concentrations of oestrogens during oestrogen
therapy (Jensen et al., 1984).
Surprisingly, we found no strong evidence that high weight
is associated with an elevated risk of endometrial cancer in
this population. Our ability to address adequately this
association was limited by the small number of cases occur-
ring in women who had never used oestrogen replacement
therapy (n=5). Cohort members tended to fall within a
rather narrow weight range and few are in the upper extreme
of weight.
Our finding of a reduced risk with increased time since
last PAP test was also somewhat unexpected. Women in this
community who have PAP tests regularly are more likely to
use oestrogen than women who do not. After adjusting for
oestrogen use, the relative risk estimates for years since last
PAP test were attenuated and the trend was no longer
statistically significant.
Our finding of better survival among oestrogen users
relative to non-users is consistent with other studies
(Underwood et al., 1979; Robboy et al., 1979; Elmwood &
Boyes, 1980; Collins et al., 1980; Chu et al., 1982; Schwartz-
baum et al., 1987). The reason for this phenomenon is not
entirely understood but may be due to an earlier diagnosis of
endometrial cancer, on average, in oestrogen users because
of more aggressive and complete medical surveillance. Our
data provide some support for this hypothesis. Only eight of
the 50 cases in our cohort were non-localised at diagnosis.
As observed by others (Mack et al., 1976; Jelovesk et al.,
1980), the association with oestrogen use for non-localised
disease, while elevated, was substantially reduced (RR=2.0)
in comparison to that for localised cancer.
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